Market Snapshot: Irhythm Technologies, Inc. (IRTC)
During the 24‑hour period ending at 11:49 AM Central Europe on Friday 23 October 2026, Irhythm Technologies, Inc. (ticker IRTC) exhibited a flat performance, with the stock price remaining unchanged at USD 119.64. The company’s current market capitalization stands at USD 3.7 billion, and a total of USD 60 million worth of shares changed hands in the last 24 hours, reflecting moderate liquidity.
Trading Dynamics
- Current supply: 32.9 million shares
- Simple moving average (200‑day): USD 115.28
- 52‑week high: USD 212 (31 October 2025)
- 52‑week low: USD 100.70 (8 October 2026)
- Year‑to‑date change: +7.06 % since the close of September 2026
These figures illustrate a company that has maintained a stable valuation trajectory while remaining within a relatively narrow price band defined by its long‑term extremes. The 200‑day moving average, a commonly used technical indicator, lies just below the current price, suggesting that the market may view the share as slightly over‑valued in the short term, yet the recent upward trend supports a bullish sentiment.
Peer Performance
Irhythm’s performance can be contextualised against a set of peer companies that have traded over the same 24‑hour window:
| Stock | Change (24 h) | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Signet Jewelers (SIG) | +1.89 % | USD 116.94 | USD 4.5 bn | 13.2 |
| Brink’s /The (BCO) | +2.29 % | USD 111.22 | USD 4.5 bn | 25.06 |
| Xenergy (XE) | +1.40 % | USD 10.63 | USD 4.4 bn | — |
| Patterson‑UTI Energy (PTEN) | –2.91 % | USD 11.34 | USD 4.5 bn | — |
| Perimeter (PRM) | +0.63 % | USD 27.15 | USD 4.4 bn | — |
Irhythm’s flat performance contrasts with the modest gains seen by Signet Jewelers and Brink’s, while Patterson‑UTI Energy experienced a decline. Notably, all peers maintain market capitalizations in the multi‑billion‑dollar range, underscoring the competitive environment within which Irhythm operates.
Strategic Context
Irhythm Technologies, Inc. is a San Francisco‑based medical device manufacturer that focuses on cardiac rhythm monitoring solutions. Since its initial public offering on 20 October 2016, the company has built a portfolio of products that cater to both clinical staff and patients, including devices for palpation, shortness of breath, and fatigue monitoring. The company’s presence on the Nasdaq exchange and its steady share price suggest a mature business model, though the lack of recent price movement may indicate that investors are awaiting new product launches or regulatory approvals before revising valuation expectations.
The information presented reflects data available as of the specified time stamp and is intended for informational purposes only.
